The FDA has granted Breakthrough Therapy designation to Verastem Inc (NASDAQ: VSTM) for the combination of its investigational VS-6766, with defactinib, for recurrent low-grade...
Let’s talk about growth stocks. These are stocks that have shown strong and sustained share price appreciation, sometimes ranging into triple-digit gains over the course of a...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Strong Sell | Strong Sell | Buy |
| Technical Indicators | Sell | Strong Sell | Strong Sell | Strong Sell | Strong Buy |
| Summary | Sell | Strong Sell | Strong Sell | Strong Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 356.30 | 360.73 | 352.94 | -2.02 | -0.56% | 15.98M | NASDAQ | |||
| 2,694.50 | 2,706.10 | 2,685.10 | -21.0 | -0.77% | 1.28M | NASDAQ | |||
| 195.19 | 196.04 | 190.49 | -2.35 | -1.19% | 17.25M | NYSE | |||
| 194.99 | 196.30 | 192.63 | -1.63 | -0.83% | 18.35M | NASDAQ | |||
| 151.78 | 153.67 | 151.20 | -1.22 | -0.80% | 9.81M | NYSE | |||
| 2,704.40 | 2,715.40 | 2,696.30 | -26.4 | -0.97% | 1.20M | NASDAQ | |||
| 2.99 | 3.72 | 2.80 | -0.910 | -23.33% | 41.29M | NASDAQ | |||
| 3.21 | 3.38 | 3.175 | -0.090 | -2.73% | 1.05M | NYSE | |||
| 3.87 | 3.90 | 3.48 | +0.260 | +7.20% | 513.02K | NASDAQ | |||
| 58.90 | 60.88 | 58.01 | -13.14 | -18.24% | 76.48M | NYSE | |||
| 34.43 | 41.50 | 33.08 | -9.07 | -20.85% | 3.60M | NYSE | |||
| 5.53 | 8.26 | 5.52 | -1.96 | -26.17% | 26.41K | NASDAQ | |||
| 2.88 | 3.40 | 2.84 | -0.580 | -16.76% | 1.74M | NASDAQ | |||
| 53.72 | 53.90 | 53.25 | +0.02 | +0.04% | 16.47M | NASDAQ | |||
| 23.98 | 24.17 | 23.67 | +0.08 | +0.33% | 48.90K | NYSE |
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing medicines to enhance the life of cancer patients. Its product in development include VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibitor that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer’s inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
